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Abstract
Background: Shigellae have become increasingly resistant to the extended-spectrum cephalosporin (ESC) worldwide
and pose a great challenge to anti-infection treatment options. The purpose of this study was to determine the
resistance, cephalosporin resistance mechanisms, virulence characteristic and genotype of ESC-resistant Shigella.
Methods: From 2008 to 2012, Shigella isolates collected from diarrhea patients were detected for antibiotics sensitivity
by disk diffusion, cephalosporin resistance determinants and virulence genes using polymerase chain reaction (PCR)
and genotyping through enterobacterial repetitive intergenic consensus sequence PCR (ERIC-PCR).
Results: A total of 356 Shigella isolates were gathered, and 198 (55.6%, 58 S. flexneri and 140 S. sonnei) were resistant to
ESC. All ESC-resistant isolates were susceptible to imipenem, and only 0.5% isolate was resistant to piperacillin/tazobactam.
ESC-resistant S. flexneri showed high degrees of resistance to ampicillin (100%), ampicillin/sulbactam (96.6%), piperacillin
(100%), trimethoprim/sulfamethoxazole (74.1%), ciprofloxacin (74.1%), levofloxacin (53.4%), ceftazidime (58.6%) and
cefepime (58.6%). ESC-resistant S. sonnei exhibited high resistance rates to ampicillin (100%), piperacillin (100%) and
trimethoprim/sulfamethoxazole (96.4%). Cephalosporin resistance genes were confirmed in 184 ESC-resistant isolates.
blaCTX-M types (91.8%, mainly blaCTX-M-14, blaCTX-M-15 and blaCTX-M-57) were most prevalent, followed by blaOXA-30 (26.3%).
Over 99.0% ESC-resistant isolates harbored virulence genes ial, ipaH, virA and sen. However, set1 were more prevalent in
ESC-resistant S. flexneri isolates than in S. sonnei isolates. ERIC-PCR results showed that 2 and 3 main genotypes were
detected in ESC-resistant S. flexneri and S. sonnei, respectively.
Conclusion: Our findings indicated that a high prevalence of ESC-resistant Shigella mediated mainly by blaCTX-M with
stronger resistance and virulence, and the existence of specific clones responsible for these Shigella infection in the
region studied.
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Background
Shigellosis continues to be a major public health prob-
lem in non-industrialized countries. It was reported that
about 91 million cases of shigellosis occurred, with
414,000 people dying in Asia annually [1]. In China, the
morbility of Shigella infections each year is unusually
high. Wang et al. [2] have reported that in 2000 0.8-1.7
million episodes of shigellosis occurred in seven different
geographical regions, China.
For shigellosis, antibiotic therapy can reduce the duration
and severity of the illness [3]. However, with the long-term
overuse of antimicrobials, the resistant Shigella has pre-
vailed all over the word, and production of extended-
spectrum β-lactamases (ESBLs) or AmpC enzymes is one
of the most important resistance mechanisms. In China
extended-spectrum cephalosporin (ESC)-resistant Shigella
spp. has also been described in recent years [3-7]. However,
as China has a vast territory area, the spectrum of anti-
microbial resistance and the mechanisms of resistance may
vary in different regions. Therefore, it is necessary to ex-
plore the variations of ESC resistance in clinical isolates of
Shigella spp. from different geographical areas.
The ability of Shigella spp. to cause shigellosis is at-
tributed to the expression of arrays of virulence genes
associated with colonization, invasion/penetration and
toxin-mediated disease, such as the invasion-associated
locus (ial), the invasion plasmid antigen H gene (ipaH),
Shigella enterotoxin 1 (ShET-1) gene (set1A and set1B),
Shigella enterotoxin 2 (ShET-2) gene (sen) and virA gene
[8,9]. Estimating the existence of virulence determinants
in Shigella would help us better understand its patho-
genicity. However, investigations into clinical Shigella
spp. virulence factors are still rare in the world.
The purpose of this study was to investigate the resist-
ance, the cephalosporin resistance mechanisms and the
prevalence of putative virulence genes in ESC-resistant
Shigella from patients with dysentery in Xiaoshan District,
suburban of Hangzhou city, Zhejiang province, China.
Finally we further ascertained the genotypes of these
strains by ERIC-PCR (enterobacterial repetitive intergenic
consensus sequence PCR) typing.
Methods
Bacterial isolates
Between January 2008 and December 2012, a total of 356
nonduplicate Shigella isolates were obtained from the fae-
ces of different diarrhea patients at Zhejiang Xiaoshan hos-
pital, Hangzhou City, Zhejiang Province, China. All isolates
were identified by VITEK 60 microbial identification sys-
tem (BioMérieux Corp., Lyon, France) and serotyped using
commercial antisera (Lanzhou Institute of Biological Prod-
ucts, Lanzhou, China). Isolates studied were taken as part
of standard patient care. Because of being focused on bac-
teria, no ethical approval was required for this study.
Antimicrobial susceptibility testing
The Shigella isolates were detected for antibiotic susceptibility
by Kirby–Bauer method for the following antibiotics (Oxoid,
Hampshire, UK), according to Clinical and Laboratory
Standards Institute (CLSI), 2012 [10]: ampicillin (AMP),
piperacillin (PIP), ciprofloxacin (CIP), trimethoprim/
sulfamethoxazole (SXT), levofloxacin (LEV), ampicillin/
sulbactam (SAM), piperacillin/tazobactam (TZP), imipenem
(IMP), cefotaxime (CTX), ceftazidime (CAZ), cefepime
(FEP) and cefoxitin (FOX). ESC-resistant organisms were
defined as isolates showing resistance or intermediate to cef-
otaxime (zone diameter ≤25 mm) or ceftazidime (zone
diameter ≤20 mm) or cefepime (zone diameter ≤17 mm)
[10]. Escherichia coli ATCC 25922 was used for antibiotic
susceptibility testing quality control.
ESBL and AmpC detection
ESC-resistant isolates were screened for ESBL production
by the phenotypic confirmatory test according to CLSI
[10]. AmpC examination was performed by the three-
dimensional extract test as described by Philip et al. [11]
for cefoxitin resistant or intermediate isolates.
ESBL, AmpC and virulence genes amplification
Detection of the ESBL genes (blaTEM, blaOXA, blaCTX-M-1, 2, 8, 9
and blaSHV) and virulence determinants (ial, iapH,
set1A, set1B, sen and virA) were performed by PCR for
ESC-resistant isolates, as described previously [3,12,13].
AmpC genes (blaMOX, blaCIT, blaDHA, blaACC, blaEBC
and blaFOX) were examined by multiplex-PCR for
cefoxitin resistant or intermediate isolates according to
Perez-Perez et al. [14]. Sequences of the primers were
given in Table 1. The PCR products for ESBL and AmpC
genes were sequenced on both DNA strands with ABI
3730XL sequencer (Perkin-Elmer) by Shanghai Sangon
Biotech. The nucleotide sequences were analyzed by
the BLAST program. For virulence genes, a representa-
tive amplicon for the each gene detected was also se-
quenced to validate that primers amplified the target
genes.
ERIC-PCR
ERIC-PCR was carried out on ESC-resistant Shigella iso-
lates using primer ERIC2: 5′-AAGTAAGTGACTGGGGT
GAGCG-3′, as described by Navia et al. [15].
Clinical data
Clinical information of the patients was collected from the
case notes. The data included date of onset, symptoms
(such as times of diarrhea, nausea, bellyache, vomiting,
fever and bloody stools), results of microscopic examin-
ation of stool (white blood cell and red blood cell), treat-
ment and duration of illness.
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Statistical analysis
Pearson’s chi-square test or Fisher’s exact test if neces-
sary was used to analyze the differences of antibiotics re-
sistance, and virulence genes, and the relationship of
virulence factors, resistance and ERIC-PCR genotypes
(SPSS 11.5). All statistical tests were two tailed, with
p < 0.05 considered statistically significant.
Results
Distribution of Shigella spp.
Among 356 Shigella isolates, S. sonnei was the most
prevalent species (n = 244, 68.5%, 244/356), followed by
S. flexneri (n = 112, 31.5%, 112/356). No sample was
positive for S. dysenteriae and S. boydii. In S. flexneri,
seven different serotypes were found: 63 type 2a, 15 type
2c, 18 type 4c, 6 type 2b, 5 type 1a, 3 type x and 2 type
3a. 35.7% (40/112) of S. flexneri and 47.1% (115/244) of
S. sonnei cases were found among patients under 5 years
old; 20.5% (23/112) of S. flexneri and 23.4% (57/244)
of S. sonnei isolates were from victims aged from
5 to 14 years; 43.8% (49/112) of S. flexneri and 29.5%
(72/244) of S. sonnei isolates were from patients
aged ≥15 years.
Antimicrobial resistance
Of the 356 Shigella isolates, 198 (55.6%, 58 S. flexneri
and 140 S. sonnei) were resistant to cefotaxime, 59
(16.6%) to ceftazidime, 66 (18.5%) to cefepime (Table 2).
The strains with resistance to ceftazidime or cefepime
were all resistant to cefotaxime. Thus, these cefotaxime
resistant strains were referred to as ESC-resistant iso-
lates in this study. In addition, in these ESC-resistant
isolates, 8 (2.2%) were resistant or intermediate to
cefoxitin.
Compared to cefotaxime susceptible S. flexneri isolates,
the ESC-resistant S. flexneri isolates were more resistant
to PIP (100% versus 85.2%, p = 0.002), SAM (96.6% versus
85.2%, p = 0.035), SXT (74.1% versus 46.3%, p = 0.003),
CAZ (58.6% versus 0%, p < 0.001) and FEP (58.6% versus
0%, p < 0.001). In S. sonnei, the ESC-resistant strains were
more resistant to AMP (100% versus 95.2%, p = 0.009),
PIP (100% versus 51.9%, p < 0.001), SAM (24.3% versus 0%,
p < 0.001), CAZ (17.9% versus 0%, p < 0.001) and FEP
(22.9% versus 0%, p < 0.001) than the cefotaxime susceptible
isolates (Table 2). Compared to ESC-resistant S. sonnei isao-
lates, the ESC-resistant S. flexneri isolates were significantly
Table 1 Primers used for PCR to detect Shigella resistance
and virulence genes



























OXA group F-ACACAATACATATCAACTTCGC 813
R-AGTGTGTTTAGAATGGTGATC
SHV group F-GCCTTTTCGGCCTTCACTCAAG 989
R-TTAGCGTTGCCAGTGCTCGATCA
TEM group F-ATAAAATTCTTGAAGACGAAA 1076
R-GACAGTTACCAATGCTTAATC
AmpC β-lactamase genes
MOX group F-GCTGCTCAAGGAGCACAGGAT 520
[14]
R-CACATTGACATAGGTGTGGTGC
CIT group F-TGGCCAGAACTGACAGGCAAA 462
R-TTTCTCCTGAACGTGGCTGGC
DHA group F-AACTTTCACAGGTGTGCTGGGT 405
R-CCGTACGCATACTGGCTTTGC
ACC group F- AACAGCCTCAGCAGCCGGTTA 346
R- TTCGCCGCA ATCATCCCTAGC
EBC group F- TCGGTAAAGCCGATGTTGCGG 302
R- CTTCCACTGCGGCTGCCAGTT
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more likely to be resistant to CAZ (58.6% versus 17.9%,
p < 0.001), FEP (58.6% versus 22.9%, p < 0.001), CIP
(74.1% versus 2.1%, p < 0.001) and LEV (53.4% versus
2.1%, p < 0.001), and less likely to be resistant to SXT
(74.1% versus 96.4%, p < 0.001). No Shigella isolates were
resistant to IMP, and Only one S. flexneri isolates was re-
sistant to TZP (Table 2).
Multiresistance among ESC-resistant Shigella isolates
Among the 356 Shigella isolates, 69 (36 ESC-resistant S.
flexneri, 23 cefotaxime susceptible S. flexneri, 6 ESC-
resistant S. sonnei and 4 cefotaxime susceptible S. sonnei)
were multidrug resistant (MDR, resistant to 3 or more
classes of antimicrobial agents), and the multi-resistance
was more frequent among S. flexneri isolates than among
S. sonnei isolates (Table 2).
Production of ESBL and AmpC
The phenotypic confirmatory test displayed that 96.0%
(190/198) ESC-resistant isolates were ESBLs positive
(Table 3). Of 8 cefoxitin resistant or intermediate iso-
lates, 2 were the three-dimensional extract test positive.
Distribution of ESBL and AmpC genes
Of the 198 ESC-resistant isolates, 105 (53.0%) were positive
for blaCTX-M-14, 28 (14.1%) for blaCTX-M-15, 22 (13.6%) for
blaCTX-M-57, 8 (4.0%) for blaCTX-M-28, 7 (3.3%) for blaCTX-M-22,
52 (26.3%) for blaOXA-30, 1 (0.5%) for blaCMY-2, and 1 (0.5%)
for blaDHA-1; 28 (14.1%) isolates carried non-ESBL gene
blaTEM-1; 8 (4.0%) strains were negative for all β-lactamase
genes detected. No isolate hosted blaSHV, blaACC, blaEBC
and blaFOX genes. And 44 (23.2%) isolates were found to
harbor ≥2 β-lactamase genes (Table 3).
Distribution of virulence genes
All ESC-resistant Shigella isolates harbored the ial, ipaH
and virA genes. The gene sen existed in 99.0% Shigella
isolates. The genes set1A and set1B were more prevalent
in S. flexneri strains than in S. sonnei isolates (p < 0.05)
(Table 4). Of 198 ESC-resistant Shigella strains, 123
(S. sonnei isolates accounting for 92.7%, 114/123) pos-
sessed the most prevalent virulence gene combination of
ia1 + ipaH + virA + sen, followed by the combination of
ia1 + ipaH + virA + set1A + set1B + sen (S. flexneri isolates
accounting for 86.8%, 46/53) (Table 4).
Table 2 Antibiotic resistance of ESC-resistant and susceptible Shigella isolates
Antibiotic
Number of isolates resistant to antibiotics (%)
ESC-resistant
S. flexneri vs ESC-resistant
S. sonnei (p value)
Total
(n = 356)





















58 (100) 51(94.4) 0.069 140(100) 99(95.2) 0.009 NA
PIP 298
(83.7)
58(100) 46(85.2) 0.002 140(100) 54 (51.9) <0.001 NA
SAM 136
(38.2)
56(96.6) 46(85.2) 0.035 34(24.3) 0 (0.0) <0.001 <0.001
TZP 1 (0.3) 1 (1.7) 0 (0.0) 3.332 0 (0.0) 0 (0.0) NA 0.119
CAZ 59 (16.6) 34(58.6) 0 (0.0) <0.001 25(17.9) 0 (0.0) <0.001 <0.001
FEP 66 (18.5) 34(58.6) 0 (0.0) <0.001 32(22.9) 0 (0.0) <0.001 <0.001
FOX 8 (2.2) 3 (5.2) 0 (0.0) 0.090 5 (3.6) 0 (0.0) 0.056 0.618
IPM 0(0.0) 0(0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA NA
SXT 304
(85.4)
43(74.1) 25(46.3) 0.003 135(96.4) 101(97.1) 0.766 <0.001
CIP 86 (24.2) 43 (74.1) 39 (72.2) 0.819 3 (2.1) 1 (1.0) 0.485 <0.001
LEV 57 (16.0) 31(53.4) 20(37.0) 0.081 3 (2.1) 3 (2.9) 0.692 <0.001
β-lactam
antibiotic +
SXT + CIP or
LEV
69 (19.4) 36 (62.1) 23 (42.6) 0.039 6 (4.3) 4 (3.8) 0.864 <0.001
AMP, ampicillin; PIP, piperacillin; SAM, ampicillin/sulbactam; TZP, piperacillin/tazobactam; FEP, cefepime; FOX, cefoxitin; IMP, imipenem; SXT, trimethoprim/
sulfamethoxazole; CIP, ciprofloxacin; LEV, levofloxacin.
p < 0.05 were considered statistically significant.
NA, not available.
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ERIC-PCR
The 58 ESC-resistant S. flexneri isolates were classified
into 8 types by ERIC-PCR. The distribution of isolates
based on this epidemiological analysis was as follows: 26
isolates in type A, 11 isolates in type B, 5 isolates in type
C, 4 isolates each in type D and type E, 3 isolates each
in type F and type G, and 2 isolates in type H. Among
the 140 ESC-resistant S. sonnei isolates, 13 different ge-
notypes (type A to M) were obtained. The major geno-
type was type A (66 isolates), followed by type B (19
isolates), type C (12 isolates), type D (8 isolates), type E
(7 isolates), type F (7 isolates), type G (6 isolates), type H
(6 isolates), type I (3 isolates), type J (2 isolates), type K
(2 isolates), type L (1 isolates) and type M (1 isolates).








(n = 198)ESBL or AmpC group ESBL or AmpC gene
Positive (n = 190) CTX-M-1 CTX-M-15 5 11 16
CTX-M-28 2 6 8
CTX-M-57 7 2 9
CTX-M-22 3 2 5
CTX-M-9 CTX-M-14 16 69 85
TEM TEM-1 2 4 6
OXA OXA-30 4 11 15
CTX-M-1+CTX-M-9+OXA CTX-M-15+CTX-M-14+OXA-30 1 0 1
CTX-M-1+ OXA+TEM CTX-M-22+OXA-30+TEM-1 0 2 2
CTX-M-57+ OXA-30+TEM-1 9 0 9
CTX-M-1+ TEM CTX-M-57+ TEM-1 2 0 2
CTX-M-1+ OXA CTX-M-57+ OXA-30 1 1 2
CTX-M-15+ OXA-30 2 8 10
CTX-M-9+ OXA+TEM CTX-M-14+ OXA-30+ TEM-1 1 3 4
CTX-M-9+ OXA CTX-M-14+ OXA-30 2 6 8
CTX-M-9+ TEM CTX-M-14+ TEM-1 0 6 6
Not detect the ESBL or AmpC genotype 0 2 2
Negative (n = 8) CTX-M-9+CIT CTX-M-14+CMY-2 0 1 1
CTX-M-1+DHA+OXA CTX-M-15+OXA-30+DHA-1 1 0 1
Not detect the ESBL or AmpC genotype 0 6 6
Table 4 Prevalence and combination of virulence genes among 198 ESC-resistant Shigella isolates
Isolate Serotype
No. (%) of isolates that produced the following: No. (%) of isolates that contained
the following combination of genes
ial ipaH virA set1A set1B sen I II III IV V
S. flexneri (n = 58) 1a (n = 2) 2 (3.4) 2 (3.4) 2 (3.4) 0 (0.0) 0 (0.0) 2 (3.4) 0 (0.0) 2 (3.4) 0 (0.0) 0 (0.0) 0 (0.0)
2a (n = 37) 37(63.8) 37 (63.8) 37 (63.8) 36 (62.1) 36 (62.1) 37 (63.8) 0 (0.0) 1 (1.7) 0 (0.0) 0 (0.0) 36 (62.1)
2b (n = 2) 2 (3.4) 2 (3.4) 2 (3.4) 0 (0.0) 0 (0.0) 2 (3.4) 0 (0.0) 2(3.4) 0 (0.0) 0 (0.0) 0 (0.0)
2c (n = 5) 5 (8.6) 5 (8.6) 5 (8.6) 0 (0.0) 0 (0.0) 5 (8.6) 0 (0.0) 5 (8.6) 0 (0.0) 0 (0.0) 0 (0.0)
4c (n = 12) 12(20.7) 12 (20.7) 12 (20.7) 10 (17.2) 10 (17.2) 12 (20.7) 0 (0.0) 2 (3.4) 0 (0.0) 0 (0.0) 10 (17.2)
58 (100) 58 (100) 58 (100) 46 (79.3) 46 (79.3) 58 (100) 0 (0.0) 12 (20.7) 0 (0.0) 0 (0.0) 46 (79.3)
S. sonnei (n = 140) 140(100) 140(100) 140(100) 12 (8.6) 19 (13.6) 138(98.6) 2 (1.4) 114 (81.4) 5 (3.6) 12 (8.6) 7 (5.0)
S. flexneri vs S. sonnei
(p value)
NA NA NA <0.001 0.003 0.360 0.364 <0.001 0.603 0.021 <0.001
Total 198(100) 198(100) 198(100) 58 (29.3) 65 (32.8) 196 (99.0) 2 (1.0) 123(62.1) 8 (4.0) 12 (6.1) 53 (26.8)
p < 0.05 were considered statistically significant.
I, ia1 + ipaH + virA; II, ia1 + ipaH + vir + sen; III, ia1 + ipaH + virA + setlA + sen; IV, ia1 + ipaH + virA + setlB + sen; V, ia1 + ipaH + virA + setlA + setlB + sen.
NA, not available.
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Discussion
This investigation reported the prevalence and resistance
of ESC-resistant Shigella, and the molecular analysis of
cephalosporin resistance genes and virulence determinants
in clinical isolates from Xiaoshan District, Hangzhou,
China collected over a period of 5 years. In the economic
undeveloped regions, S. flexneri is the most frequently iso-
lated Shigella species. A similar situation also exists in
China, according to previous data [2,4,6,16-18]. However,
in our study S. sonnei was the most common cause of
bacterial dysentery, which was consistent with the findings
in industrialized countries. In recent years, the data from
Kaengkhoi District of Thialand, Ho Chi Minh City of
Vietnam, South Korea, Taiwan and the East, North and
Northeast regions of China, which are the newly indus-
trialized regions, also displayed a striking species shift
from S. flexneri to S. sonnei [18-22]. Therefore, the spe-
cies transition of shigellosis in the present study may
be related to the economic growth in Xiaoshan District,
suburban of Hangzhou city with higher economic indica-
tors. Of course, other factors may also play a role and need
further researches.
Through the resistance data analysis, we found that
more than half of the S. flexneri and S. sonnei isolates were
resistant to ESC (cefotaxime). Data from 8 Asian countries
showed a high prevalence of resistance to the frontline an-
tibiotics AMP (53.0%) and SXT (81.0%) among Shigella
isolates [21]. However, the resistance rates to the both
drugs among all our Shigella isolates were more higher
(AMP, 97.8%; SXT, 85.4%), and were consistent with the
data from other investigations, mainland China [6,16,17].
The data from Table 2 showed that SAM was not appro-
priate for the treatment of diarrhea caused by S. flexneri,
regardless of the strains with ESC-resistance (96.6%) or
susceptibility (85.2%); On the contrary, it can be used to
prescribe for S. sonnei infections, especially for the cefo-
taxime susceptible strains. Although the resistance rate of
Shigella to PIP was high (83.7%) in this study, TZP was of
very high anti-Shigella activity (Table 2).
If the inhibition zone diameter of CAZ is ≥21 mm or
that of FEP ≥18 mm, the two antibiotics can be re-
ported susceptibility for enterobacteriaceae, irrespective
of the isolates producing ESBLs or not, according to
the CLSI [10]. In all Shigella isolates studied, a similar
results of resistance to CAZ and FEP (16.6% and 18.5%)
were observed, which were higher than that reported by
Yang et al. (5.2% and 6.5%) [16]. However, the resistance
rates in Table 2 indicated that the two antibiotics were
more suitable for the empiric therapy of the infection
of ESC-resistant S. sonnei than that of ESC-resistant
S. flexneri infection.
Fluoroquinolones are the popular antibiotics for the
treatment of serious shigellosis in both adults and chil-
dren. Research results from Gu et al. [23] showed the
resistance rate to CIP was 29.1% between 2007 and 2009
in the Asia-Africa area. Data from Henan Province,
China displayed that 21% and 79% of S. flexneri strains
showed high- or low-level resistance to CIP, respectively
[6]. Yang et al. [16] reported that 27.9% and 9.7%
Shigella were resistance to CIP and LEV, respectively, in
Anhui province, China. In our study, a similar resistance
rate to CIP (24.2%) and a higher resistance rate to LEV
(16.0%) were exhibited (Table 2). Among the fluoro-
quinolone resistant isolates, 95.3% (82/86, resistance to
CIP) and 89.5% (51/57, resistance to LEV) strains belonged
to S. flexneri. The possible cause was that S. flexneri
isolates often possessed plasmid-mediated quinolone
resistance (PMQR) determinants or mutations in quin-
olone resistance-determining regions (QRDR) of gyrase
and topoisomerase genes. This situation had been de-
scribed in isolates from other regions of China by
Zhang et al. [4], Zhu et al. [24] and Pu et al. [25].
So far, at least 109 variants of CTX-M enzymes (CTX-
M-1 to 124) have been described. Of these CTX-Ms, 19
variants (CTX-M-15, 16, 19, 23, 25, 27, 32, 35, 37, 40,
42, 53, 54, 55, 57, 58, 62, 64, 82, 93) exhibit the in-
creased hydrolysis activity against ceftazidime, and the
others display a much higher rate of hydrolysis of cefo-
taxime than ceftazidime [26]. CTX-M-15 is the most
usually detected CTX-M variant that hydrolyze ceftazi-
dime at high level in enterobacteriaceae [26]. In this
study, 28 blaCTX-M-15 positive ESC-resistant Shigella iso-
lates were all resistant to ceftazidime (data not shown).
No other CTX-M variant genes mediating high level cef-
tazidime resistance were found (Table 3). In the blaCTX-M
genes with higher catalytic efficiencies against cefotaxime
than ceftazidime, blaCTX-M-14 was the most prevalent one
(53.0%), and coincides with the data published worldwide
in clinically important pathogens [26]. OXA-30 belongs
to the class D oxacillinase group III, and mediates resist-
ance to cefepime but not ceftazidime [27]. Unfortunately,
52 (26.3%) of our ESC-resistant Shigella isolates hosted
blaOXA-30, and 12 of them carried blaCTX-M-15 concomi-
tantly and conferred resistance to cefotaxime, ceftazidime
and cefepime (Table 3). In the past decade, an emergence
of ESBL-producing Shigella spp. carrying different types of
ESBL genes has been described in different countries and
regions [28]. However, only a few studies have reported in
the world the existence of AmpC β-lactamases encoded
by blaCMY-2 or blaDHA-1 in Shigella spp. [4,25,28-31]. In this
study, we also found 2 AmpC β-lactamase producers with
blaDHA-1 and blaCMY-2 in the three-dimensional extract test
positive Shigella strains. The blaCMY-2 and the blaDHA-1
existed in 1 S. flexneri with blaCTX-M-14 and 1 S. sonnei with
blaCTX-M-15 and blaOXA-30, respectively (Table 3).
In this study, we detected several pathogenic genes
(ial, ipaH, set1, sen and virA) for 198 ESC- resistant
Shigella isolates (Table 4). It has been shown that ial
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takes responsibility for penetration of epithelial cell by
Shigella and ipaH also for spread from cell to cell
[32,33]. All Shigella species studied were positive for the
ipaH as expected because this gene exists in multiple
copies on both the chromosome and the plasmid of
Shigella. Conversely, the ial gene is exclusively located
on the plasmid and was only detected in some Shigella
isolates [8]. Indeed, less frequent examination of ial
gene had been described by Luscher and Altwegg [34],
Kingombe et al. [35] and Thong et al. [36]. However,
this gene was found in all our ESC-resistant Shigella
strains. Another virulence factor VirA is involved in the
uptake, motility, and cell to cell transmission of Shigella
within the human host. It is an essential virulence factor
in Shigella disease pathogenesis [9]. The positive rate of
virA implied all the isolates of our collection might have
the ability (Table 4). The set1 chromosomal gene encodes
Shigella enterotoxin 1 (ShET-1, composed of one A and
five B subunits), which is generated by S. flexneri (mainly
in type 2a) and not found in other Shigella spp.
[8,12,36-41]. The sen gene encoding Shigella enterotoxin 2
(ShET-2) is carried on a 140 MDa virulence plasmid. And
the sen is present in all Shigella species. The both toxins
are deemed to play a part in the clinical manifestation
of shigellosis [8]. In our study, 79.3% of ESC-resistant
S. flexneri strains were found to be set1A and set1B
positive (62.1% isolates were serotype f2a, Table 4), and
this is agreement with the previous results; however,
17.1% (24/140) ESC-resistant S. sonnei isolates also car-
ried set1A and/or set1B genes (Table 4). The set1A and
set1B genes are located on the she pathogenicity island
(PAI), a chromosomal, laterally acquired, integrative
element of S. flexneri [37]. Integrase-mediated excision
can occur for the she PAI, and result in the formation
of a circular excision product, which is a substrate for
lateral transfer processes e.g. conjugation, packaging
into phage particles and recombinase-mediated integra-
tion into the chromosome [42]. This may be the cause
that the two determinants can be found in our ESC-
resistant S. sonnei isolates studied. And the deficiency of
set1A or set1B, or the existence of point mutations in the
primer binding sites may be the possible explanation for
the both genes not coexisting in some ESC-resistant S.
sonnei isolates (Table 4). Furthermore, we found that the
S. flexneri isolates with set1 were more resistance to CIP,
LEV (p < 0.001, each) and FEP (p = 0.019) than those with-
out set1; for S. sonnei, the set1 positive isolates were more
likely resistance to SAM (p < 0.001), CIP, LEV (p < 0 .001,
each) and FEP (p = 0.002), and more likely sensitivity to
CAZ (p = 0.005) than set1 negative ones (data not shown).
Nevertheless, we do not think there was correlation be-
tween set1 and the antibiotics resistance, because none
of reports have described currently that the invasion
genetic elements carrying virulence genes known contain
resistance determinants simultaneously in Shigella spp..
These resistance differences may be only due to the spread
of resistant plasmids among the different strains.
The results of ERIC-PCR typing showed that most of the
cases of ESC-resistant S. flexneri and S. sonnei infections
were caused by several identical strains, respectively [for
S. flexneri isolates, the percentage of type A and type B
accounting for 63.8% (37/58); for S. sonnei, type A, type B
and type C encompassing 69.3% (97/140) of the isolates].
This indicates that clonal dissemination was likely to con-
tribute most to the spread of ESC-resistant S. flexneri and
S. sonnei within the region studied. Of 46 ESC-resistant
S. flexneri isolates with the second largest number of the
virulence gene composition (ia1 + ipaH + virA + setlA +
setlB+ sen) being resistant to 4 to 8 antibiotics, 60.3%
belonged to type A (43.1%) and type B (17.2%). Of 114
ESC-resistant S. sonnei isolates with the first largest
number of the virulence gene composition (ia1 + ipaH +
vir + sen) being resistant to 3 to 6 antibiotics, 71.1%
belonged to type A (57.9%) and type B (13.2%), but isolates
that hosted the set1 gene were more heterogeneous in
ERIC-PCR pattern.
In the present study all the Shigella strains were iso-
lated from intestinal clinic patients. No patients had
been hospitalized or died following episodes of shigello-
sis. According to the clinical reports, early stage of shig-
ellosis the patients infected by ESBL genes positive
isolates were not more severe than those of the patients
infected by ESBL genes negative isolates. However, most
of these patients had longer course of treatment, because
physicians used to treat diarrhea by prescribing cefo-
taxime or ceftriaxone (particularly for children) in the
region studied. When treatment failed, other drugs (such
as fluoroquinolone or β-lactamase inhibitors) would be
used as a substitute for continuing treatment. In addition,
all the patients with Shigella infection in the study were
treated with antibiotics, therefore, we had no relevant data
to compare the course of disease treated using antibiotics
with that of disease treated without antibiotics.
Conclusions
This investigation found a striking difference from other
regions of China with relatively low economic status in
the distribution of species, from S. flexneri to S. sonnei,
and a high prevalence of ESC-resistance among Shigella
isolates. Antibiotic susceptibility testing displayed ESC-
resistant S. flexneri isolates were much more resistant than
ESC-resistant S. sonnei isolates. The analysis of extended-
spectrum cephalosporin resistance genes showed the
spread of the Shigella harboring a combination of genes
blaCTX-M-15 and blaOXA-30. This combination may be a ser-
ious threat to infection treatment because it is spread by
conjugation and it displays high levels of resistance to cef-
otaxime, ceftazidime and cefepime. We also described the
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prevalence of virulence genes in ESC-resistant Shigella,
which may provide clues about the pathogenicity differ-
ence of this type of bacteria. ERIC-PCR typing supported
the existence of specific clones responsible for the ESC-
resistant S. flexneri and S. sonnei infection cases in the
region studied. In China, especially in some undeveloped
regions, there were limited and sporadic data on the
epidemiology of Shigella spp. Therefore, we suggest the
Ministry of Health National Antimicrobial Resistance In-
vestigation Net (Mohnarin) to reinforce the surveillance
for the development of antibiotic resistance and take mea-
sures to control shigellosis in China.
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